Results 51 to 60 of about 10,858 (213)

A Phase 2b randomised, controlled, partially blinded trial of the HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): Weeks 24 and 48 Efficacy, Safety, Bone and Metabolic Results [PDF]

, 2016
Background BMS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maintain in-vitro antiviral activity while minimising off-target effects.
Avihingsanon, Anchalee, Echevarría, Juan, Gupta, Samir K., Hanna, George J., Joshi, Samit R., Lataillade, Max, Lombaard, John, McComsey, Grace A., Orrell, Catherine, Osiyemi, Olayemi, Ray, Neelanjana, Santoscoy, Mario, Stock, David A.   +12 more
core   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: From treatment to prevention [PDF]

, 2013
The HIV epidemic continues unabated, with no highly effective vaccine and no cure. Each new infection has significant economic, social and human costs and prevention efforts are now as great a priority as global antiretroviral therapy (ART) scale up ...
A Bedri, A Calmy, A Coovadia, A Coovadia, A De Luca, A Hill, A Kunz, A Moorthy, A Moorthy, A Shibata, A Zolopa, AN Phillips, AY Liu, BE Nichols, BE Nichols, BG Brenner, BR Yehia, C Laurent, C Pretorius, C Unge, C Unge, C Zeh, CA Boucher, CB Hurt, CJ Hoffmann, CL Townsend, CS Chasela, D Descamps, D Frentz, D Frentz, D Persaud, DA van de Vijver, DA van de Vijver, DADS Group, DAMC Van de vijver, David A M C Van de Vijver, DC Vissers, DE Bennett, DJ McColl, E Arrive, E Bendavid, E Mills, EM Connor, ER Cooper, ES Daar, F Doualla-Bell, F Tanser, F van Leth, F van Leth, FA Frankel, FDA, FJ Palella Jr, G Jourdain, G Jourdain, GL Melikian, GN Nikolenko, H Sunpath, HM Coovadia, I de Vincenzi, I Thior, J Bor, J Fogel, J Marrazzo, J Mermin, J Mermin, J Ren, J Vercauteren, JA Hontelez, JA McIntyre, JB Nachega, JE Gallant, JE Gallant, JM Baeten, JM Baeten, JM Fogel, JM Whitcomb, JO Kahn, Joint United Nations Programme on HIV/AIDS (UNAIDS), JW Eaton, KA Delviks-Frankenberry, KN Althoff, L Ryom, L Van Damme, L Wittkop, LA Guay, M Lallemant, M Mirochnick, MA Fischl, MA Thompson, MA Wainberg, Mark A Wainberg, MC Hosseinipour, MC Thigpen, MD Miller, MS Cohen, N Ford, N Shaffer, N Sood, NA Martinson, NA Wade, NE Mackie, NI Kumwenda, P Mugyenyi, PR Meyer, Q Abdool Karim, R Granich, R Gupta, R Kaplan, Ravindra K Gupta, RE Barth, RF Schinazi, RF Schinazi, RK Gupta, RK Gupta, RL Hamers, RL Hamers, RL Shapiro, RM Granich, RM Grant, RM Gulick, RM Mainardes, RS Veazey, S Lockman, S Loubser, S Rosen, S Staszewski, S Staszewski, S Sungkanuparph, S Yerly, SH Eshleman, SH Yap, Sheetal Manicklal, SL Spruance, T Flys, U CHIC, UL Abbas, UM Parikh, UNAIDS, UNAIDS, V Cambiano, V von Wyl, VD Lima, VS Gill, WHO, WHO, Z Shubber   +145 more
core   +4 more sources

The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang, Taoran Geng, Ruirui You, Huiling Xiang, Ying Guo, Xiaohong Gao, Guojun Li, Qun Zhang, Xiaoping Wu, Haifang Cao, Wenhua Zhang, Jia Shang, Jiawei Geng, Lihong Qu, Shuilin Sun, Xiulan Xue, Rui Zhao, Lihua Zhong, Guohong Ge, Yanbin Wang, Jianqi Lian, Ming Liang, Qing Ye, Xiaoyan Wang, Xiaoqing Guo, Dan Xu, Yiqi Yu, Feng Sun, Chao Qiu, Jiming Zhang, Yuxian Huang, Wenhong Zhang, Xiaolong Qi   +32 more
wiley   +1 more source

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide

Frontiers in Pharmacology, 2020
Background: HIV pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine is effective when taken daily. Previously, we developed a urine assay capable of detecting the prodrug tenofovir (TFV) in patients taking tenofovir disoproxil fumarate (TDF ...
Linden Lalley-Chareczko, Emily Hiserodt, Ganesh Moorthy, Athena Zuppa, Karam Mounzer, Helen Koenig, Helen Koenig   +6 more
doaj   +1 more source

Prospective study to assess progression of renal markers after interruption of tenofovir due to nephrotoxicity [PDF]

, 2016
Background. Prospective studies about the reversibility of tenofovir disoproxil fumarate- (TDF-) related renal impairment remain scarce. Methods. This is an observational prospective study including all patients that presented at our HIV Unit who ...
Bonjoch Badia, Anna, Clotet Sala, Bonaventura, Echeverria Liras, Patricia, Estany Quera, Carla, Negredo Puigmal, Eugènia, Puig, Jordi, Pérez Álvarez, Nuria   +6 more
core   +5 more sources

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann, Ulrike Wieland, Steffi Silling, Frank Oellig, David Chromy, Julia Hyun, Thilo Gambichler, Alexander Kreuter   +7 more
wiley   +1 more source

Discordant Liver Fibrosis Predictors in Virologically Suppressed People Living with HIV without Hepatitis Virus Infection

Diagnostics, 2021
Severe liver fibrosis (LF) is associated with poor long-term liver-related outcomes in people living with HIV (PLWH). The study aimed to explore the prevalence and predictors of LF and the concordance between different non-invasive methods for the ...
Barbara Rossetti, Valentina Borgo, Arianna Emiliozzi, Marta Colaneri, Giacomo Zanelli, Miriana d’Alessandro, Davide Motta, Laura Maiocchi, Francesca Montagnani, Maria Cristina Moioli, Chiara Baiguera, Margherita Sambo, Teresa Chiara Pieri, Pietro Valsecchi, Raffaele Bruno, Massimo Puoti, Massimiliano Fabbiani   +16 more
doaj   +1 more source

A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection [PDF]

, 2014
A number of antiviral agents used against Human Immunodeficiency Virus (HIV) infection and hepatitis B virus (HBV) mono or co-infection have been associated with real nephrotoxicity (including tenofovir disoproxil fumarate (TDF), atazanavir, indinavir ...
Abbas, R., Baer, R., Boyd, M., Gracey, D., Holt, S., Irish, A., Levy, M., Mudge, D., Sevastos, J., Walker, R.   +9 more
core   +3 more sources

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

Hepatology Research, EarlyView.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami, Soranobu Ninomiya, Takayasu Ideta, Ayumu Kanbe, Toshihide Maeda, Daisuke Minowa, Daisuke Taguchi, Masaya Kubota, Hiroyasu Sakai, Kenji Imai, Yasuko Yamamoto, Hiroyasu Ito, Kuniaki Saito, Osamu Yoshida, Yoichi Hiasa, Masahito Shimizu   +15 more
wiley   +1 more source